FinVector (formerly Ark Therapeutics Oy) needed a BSL-2 cell culture manufacturing plant based on single-use process technology and had a short timeline to realize it, so they turned to NNE for the solution.
Being a research and development company, FinVector had little experience with major engineering projects. So when it needed a facility established quickly using a single-use solution, FinVector looked for a partner with proven experience in single-use process technology and fast-track engineering.
Bringing experience to the table
With our expertise in single-use technology and award-winning fast-track solutions, NNE was a perfect fit. We were given complete responsibility for all site activities, including the design, installation, testing and qualification of cleanrooms, HVAC, media, clean utilities and process equipment for filling and primary packaging. NNE was able to provide a unique, tailored solution in just 16 months.
Unique facility for breakthrough products
The biological manufacturing operations provide process development and manufacturing capabilities for internal Ark Therapeutics programs, as well as for third party clients for a variety of stages in therapeutic development. In the production facility, FinVector is able to produce ground-breaking gene-based biopharmaceutical products based on modified viral particle technologies, as well as other biopharmaceuticals, up to biosafety level 2 (BSL-2).
Quick facts
Customer
FinVector (formerly Ark Therapeutics Oy)
Country
Finland
Project duration
Feb. 2007 – Jun. 2008
Services provided
Basic design, detailed design, procurement support, installation management, commissioning supervision, qualification (up to operational qualification), validation support
